Abstract The genomic revolution in medicine has not escaped attention of clinicians and scientists involved in medical management and research studies of immune thrombocytopenic purpura (ITP). In principle, ITP biology and care will benefit greatly from modern methods to understand the patterns of gene expression and genetic markers associated with fundamental parameters of the disease including predictors of remission, risk factors for severity, determinants of response to various therapies, and possibly biological sub-types. However, applying modern genetics to ITP carries severe challenges: (a) Achieving adequate sample sizes is a fundamental problem because ITP is rare (and in pediatric ITP, chronic cases constitute only about one fourth of the total); (b) familial transmission of childhood ITP is so rare that a convincing pedigree requires consideration of other immunologic or hematologic disorders; (iii) ITP is probably biologically heterogeneous, based on clinical observations, immunological studies, and animal models. Here we review the advantages and disadvantages of potential genetic approaches. Sufficient information is available to set reasonable bounds on which genetic analyses of ITP are feasible and how they are most likely to be accomplished. The highest priority is for accurate phenotypes to compare to genetic analyses. Several registries worldwide hold promise for accomplishing this goal.
Introduction
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder and the most common cause of isolated thrombocytopenia in children. ITP is diagnosed clinically, based upon onset of thrombocytopenia in the absence of other hematologic abnormalities, or other causes of low platelets, and with a characteristic blood smear. Degree of thrombocytopenia is highly variable, and while bleeding manifestations also vary, severe bleeding is rare. Around 50% of typical childhood acute ITP is preceded by a viral or bacterial infection and commonly resolves within weeks to months without treatment. The incidence of pediatric ITP is on the order of four to six cases per 100,000 population annually. About one fourth of these patients go on to chronic disease (which depends in part on the definition of "chronic" as discussed below). For the US pediatric population (∼70 million under age 18), this corresponds to ∼3,000-4,000 total cases annually, and around 1,000 new patients with chronic ITP each year. The prevalence of chronic ITP is somewhat higher, as patients continue to manifest their illness. Similar calculations can be done for any country or region, and an upper bound on number of cases can be set. These numbers inform the analyses that are possible.
While ITP in adults is defined as it is in children, fewer adult cases are acute and self-resolving. In young adults, particularly females, cases are more likely than in children to represent an initial manifestation of lupus, and in older adults, many cases are related to lymphoproliferative disorders. Overall though, typical adult primary ITP is very similar clinically to chronic pediatric ITP. Splenectomy remains a more common treatment in adult than pediatric disease by a wide margin. Whether all adult and pediatric chronic ITP cases are safely "lumped" together for the purpose of genetic analyses remains a matter of conjecture, but we and most treaters believe that the condition in older teens and young adults is indistinguishable clinically and biologically. Genes and pathways identified as important modifiers of lupus and lupus-like states are likely to be important candidate genes for ITP evaluation as well.
Based on the lack of familial cases in ordinary ITP, it is fair to ask, "Why is genetic analysis important at all?" In our view, a search for genes and pathways which modify ITP will improve research and future clinical practice in the field in resourceful/multi-sided ways:
Novel genes and loci identified in unbiased genetic screens (genetic association studies or "transcriptome" analysis) may help elucidate biology of ITP, and suggest the possibility of novel testing for biomarkers of disease, or targets for therapy. These may be true even if the relative contribution of a novel gene to biological variability in ITP is small.
Candidate genes based on our current understanding of pathogenesis and pharmacologic responses can be evaluated to confirm or potentially to rule out postulated contributions.
Pharmacogenomic correlates of response to treatments may have direct clinical relevance in choosing therapies for patients.
Definitions
The temporal cutoff between "acute" and chronic ITP in childhood is arbitrary, and opinion about the best time-point is evolving. While chronic ITP was traditionally defined by a platelet count of ≤150×10
9 /L at 6 months following diagnosis, remissions after 6 months are common. The Intercontinental Childhood ITP Study Group (ICIS) has used a 12-month cutoff to define chronicity. It remains to be proven how best to apply these newer proposed criteria to pediatric ITP. Various defining criteria have been published. For further clinical review, we refer to the guidelines of The American Society of Hematology, the UK guidelines, the AIEO ITP guidelines, the references cited therein, and the recently established criteria by Rodeghiero et al. [1] [2] [3] [4] .
Differences in clinical ITP management approaches are substantial [5] . "Which drug treatment should be chosen in refractory patients?" and "How can we predict disease progression and treatment response?" are examples of unanswered questions.
Therapeutics in ITP vary broadly, including immunomodulatory agents, immunosuppression, and more recently thrombopoietin-receptor agonists. A detailed discussion is beyond the scope of this paper, except to say that responses to individual therapies among patients also vary widely. Biological heterogeneity in ITP course, duration, and/or in drug responsiveness are crucial "phenotypes" and may prove to have genetic bases. Although several lines of investigation have focused on the pathophysiology of this immune-mediated disease, little is understood about the underlying cause(s) of ITP (reviewed by [6] [7] [8] ).
Importance of registries
As is true for many rare disorders, we believe that carefully designed multicenter registries are the only means to achieve sufficient level of detail in salient outcomes of ITP for comparison to genotype or gene expression results. While the extant registries (Table 1) vary by methodology, they have in common the ability to discern various patient characteristics including demographics, duration of disease, and response to treatment(s). The largest registries are on the scale of a few hundred to 1,000 to 2,000 patients. None have more than a few hundred chronic ITP patients. This is an important number in considering applicability of genome-wide approaches, discussed below.
In ITP, several key features of phenotype can only be determined by observation over time: Differentiation of chronic from acute disease (by any of the definitions above) necessitates either a retrospective diagnosis after the diagnostic time interval (e.g., 6, 9, or 12 months) or prospective analysis with this length of follow-up. As a practical matter for the current state of ITP registry research, it would be helpful if all registries attempt to ascertain the platelet count status at 6, 9, and 12 months from diagnosis to facilitate comparisons at a later time.
Longitudinal follow-up at intervals after 12 months can also define a "remission" status in chronic ITP. For the purpose of genetic analysis, we propose that very long-term followup will lead to a problem of diminishing returns. The fraction of patients achieving remission after more than 2 years is certainly too small for any primary genetic analyses, but would be amenable to analysis of novel candidate genes once they are discovered. The same can be said for patients with "relapse" of ITP months or years after achieving a remission of all therapies. While overt relapse is an important phenotypic characteristic, it occurs in only a small fraction of ITP patients (perhaps 5%), and insufficient power would be available for primary analysis of this outcome in all of the world's registries combined.
Response to therapies is a key component of the ITP phenotype, but this outcome is highly variable among ITP patients, and there is no clinical consensus for a particular treatment at a particular time in the disease course for various ITP clinical situations. Therefore, even in the largest registries, only a minority of patients would have received any particular therapy. Less severely affected patients will receive fewer pharmacologic treatments, and even severely affected, chronic ITP patients achieve experience with various therapies only over months or years. Furthermore, in clinical practice and most registries (as opposed to prospective research studies), pre-and posttherapy platelet counts will not be reliably available for each treatment in all circumstances.
Types of genetic analysis
Two ITP multicenter registries already include the collection of DNA samples, and others aim to extend their registries in similar way. Advantages and disadvantages of different genetic approaches impact the possibilities of genetic studies in ITP (Table 2) .
Family-based linkage studies
Family-based linkage studies will be limited since familial cases of ordinary ITP are very rare. It is unlikely that such cases will be found in significant numbers in registries. Our center's experience is not more than a handful of convincing pedigrees of "familial" ITP in more than 1,000 consecutive probands. Other genetic disorders with thrombocytopenia, which may be (mis) diagnosed as ITP in the proband, include myosin heavy chain disorders (MYH9 gene on chromosome 22q11.2, Online Mendelian Inheritance in Man (OMIM) #605249), autoimmune lymphoproliferative syndrome, related to defects in FAS pathway (OMIM 601859), and Wiscott-Aldrich Syndrome/X-linked thrombocytopenia (OMIM 301000; http://www.ncbi.nlm.nih.gov/sites/omim queried 7/31/09) In these times of ready single nucleotide polymorphism (SNP) chip analysis and whole genome sequencing, genome-wide association studies (GWAS) are technically feasible and could reveal novel insights especially in the pathophysiology and disease susceptibility. However, the most challenging requirement is to achieve adequate sample Number of cases calculated with the "Power for Genetic Association analyses 1" program [13] . Parameters used: incidence 5/100,000 (0.00005), type I error (alpha)=0.05, effective degree of freedom=1, control to case ratio=1. Only numbers in italics are sample sizes likely to be achieved in the pediatric ITP population a Co-dominant (2 degrees of freedom): This model tests the effect of each genotype independently; therefore, it is assumption free Asian (Chinese) [30] 136 controls size to conduct association studies with reliable and conclusive results. Three major factors affect the sample size, "n" required to have significant results. First, the smaller the effect of any given gene, the larger a population will be required to see the effect. GWAS studies on populations of many thousand individuals can detect relative risks much less that 1.5-fold, but these will be impossible in chronic ITP. Second, rare but important genes responsible for familial ITP would be very difficult to ascertain in population studies. For all practical purposes, alleles with less than 5% or 10% prevalence in the population would need enormous "risk" to be discovered by unbiased approaches. Third, when the number of loci tested becomes very large (Affymetrix 6.0 SNP-chips allow testing of nearly 10 6 loci and up to 2.5 million SNPs can be inferred), an enormous statistical price is paid for multiple comparisons. For the traditional accepted type I error of 5%, to test one million loci means that p values need to be less than 5×10 −8 to be statistically significant. This fact alone drives sample sizes into the thousands for unbiased analyses. (Table 4) . Results of these studies have to be confirmed in larger cohorts to make conclusions about pathogenetic implications. These reports include diverse groups of patients and populations, which can make the analyses difficult to generalize. Several are of borderline statistical significance (p values not much less than 0.05), perhaps because of small sample size, chance associations, or biological heterogeneity. Only by replication in additional populations will true significance become clear. Investigators will achieve most meaningful results if they are able to assign patients definitively to acute and chronic ITP phenotypes (in case these are biologically distinct). It is imperative to have controls which match the ethnic and racial background of the case group: Frequencies of polymorphisms differ among groups, so that overrepresentation of different ethnic groups between cases and controls by ethnicity complicates analysis and accurate interpretation of genetic data [9] .
Comparative genomics
Convincing familial or breed-specific ITP is common in some dog groups, including old English sheep dogs, It is controversial if a gene, which may be a key receptor protein for the chimeric anti-CD20 antibody, rituximab, namely the FCGR3A V/V allele, influences the response to rituximab [10, 11] . The identification of further candidates in the metabolism of rituximab would make pharmacogenetic studies in ITP feasible.
6-Mercaptopurine and the related azathioprine must be converted to active 6-thioguanine, for biological activity; these compounds are then cleared in part by thiopurinemethyltransferase (TPMT). A common allelic variant of the TPMT gene (approximately 10% in Caucasians) causes slow elimination of the active drug, and homozygotes for this variant (about 1% in the population) have high risk of severe myelosuppression and other toxicities [12] .
Conclusion
Logistic and statistical considerations set strong boundaries on how genetic methods may be used for analysis of pediatric ITP pathophysiology and phenotypic expression. To the extent that ITP is biologically heterogeneous (T vs. B cell origin, for example), these restrictions will be even more severe.
However, the several ITP registries worldwide will play an important role in defining phenotype and identifying subjects for feasible genetic studies. We propose that if the registries can have common phenotypic data elements, they will be much more powerful tools to assist basic scientists studying mechanisms of disease. If registries and samples were pooled collaboratively, larger sample sizes would be possible but replication of analyses would be hard. If registries are kept distinct, replication data sets will be easy to come by, but sample sizes will be small. Pharmacogenetics and comparative genomics have not yet been optimally tested. Unbiased GWAS studies will be particularly challenging due to sample size problems.
